Outcomes based on fludarabine-melphalan vs other RIC regimen. Shown are Kaplan-Meier curves for overall survival and cumulative incidence (A) for nonrelapse mortality (B) and relapse based on telomere length and reduced-intensity regimen type (C). Fludarabine/melphalan (Flu-Mel)-based regimens are indicated by dashed lines; other RIC regimens are indicated by solid lines. Telomere length groups are indicated by color: the shortest quartile (red), second and third quartiles (green), and the longest quartile (blue). The distribution of melphalan doses is presented in supplemental Figure 7. Outcomes by telomere length quartiles in RIC regimen groups are presented in supplemental Figure 8.